Change text size: Sm  Med  Lg
ReSTOR Clinical StudiesAlcon® AcrySof® ReSTOR® IOL Clinical Studies
AcrySof ReSTOR IOL Clinical Results

AcrySof® ReSTOR® Clinical Results

During the AcrySof® ReSTOR® IOL clinical studies, patients' lifestyles were enhanced through improved vision and greater freedom from reading glasses and bifocals. In fact, according to the AcrySof® ReSTOR® IOL clinical studies, 80% of AcrySof® ReSTOR® IOL patients found they no longer depended upon their glasses, compared to only 8% of patients with monofocal lenses following bilateral cataract surgery.

Additionally, the AcrySof® ReSTOR® IOL clinical studies indicated that nearly 94% of the study subjects were so satisfied with their improved vision that they would have the AcrySof® ReSTOR® IOL implanted again.

Clinical studies with the AcrySof® ReSTOR® IOL as compared to a monofocal control demonstrated:

  • Highest level of freedom from glasses ever demonstrated in an IOL clinical study
  • Excellent near visual acuity without compromising distance vision
  • No statistically significant differences in the incidence of severe visual disturbances

Copyright © 2012 Novartis AG a global company based in Basel, Switzerland. The information and materials within this section pertain to the U.K. market only. Not all products are approved in every marked and approved labeling and instructions may vary by local country. See the Alcon Privacy Policy and Terms & Conditions for the use of this site.